Extended Anticoagulation with Reduced-Dose Non-inferior to Full-Dose Apixaban for the Prevention of Recurrent VTE in Patients with Active Cancer By Ogkologos - April 29, 2025 695 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the API-CAT study Source RELATED ARTICLESMORE FROM AUTHOR Solid Organ Transplant Recipients with Pretransplant Cancer Have an Elevated Risk of Posttransplant Cancer of the Same Cancer Type Population-based lung cancer screening can reduce mortality in people who have never smoked, study shows in China EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib MOST POPULAR ΣΑΡΚΩΜΑ February 7, 2019 NCI Launches New Resource for Specimens and Data from Cancer Clinical... April 2, 2018 2020 Cancer Incidence and Mortality in EU-27 Countries July 24, 2020 Breast Cancer May Spread by Recruiting Nearby Sensory Nerves September 20, 2024 Load more HOT NEWS A Phase III Study of Spartalizumab in Combination with Dabrafenib and... Pattern of DNA Damage Links Colorectal Cancer and Diet High in... ΚΑΡΚΙΝΟΣ ΤΟΥ ΜΑΣΤΟΥ Breast Cancer Survivor Given 12 Months to Live After Left Side...
